UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/581,763	08/07/2007	Judith Donovan	38-21(52949)B	6571	
Timothy K. Bal	7590 03/03/201 I. Ph.D.	EXAMINER			
Monsanto Company c/o Gail Wuellner 800 North Lindbergh Boulevard Mail Zone E2NA			KUBELIK, ANNE R		
			ART UNIT	PAPER NUMBER	
St. Louis, MO	53167		1638		
			MAIL DATE	DELIVERY MODE	
			03/03/2010	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary		Application No.	Applicant(s)		
		10/581,763	DONOVAN ET AL	DONOVAN ET AL.	
		Examiner	Art Unit		
		Anne R. Kubelik	1638		
Period fo	The MAILING DATE of this communication a or Reply	ppears on the cover sheet with t	the correspondence ad	dress	
A SHO WHIC - Exter after - If NO - Failur Any r	ORTENED STATUTORY PERIOD FOR REF CHEVER IS LONGER, FROM THE MAILING asions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication. It period for reply is specified above, the maximum statutory period re to reply within the set or extended period for reply will, by state eply received by the Office later than three months after the mailed patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 1.136(a). In no event, however, may a reply od will apply and will expire SIX (6) MONTHS ute, cause the application to become ABANI	TION. be timely filed from the mailing date of this co DONED (35 U.S.C. § 133).		
Status					
2a)⊠	Responsive to communication(s) filed on <u>18</u> This action is FINAL . 2b) The Since this application is in condition for allow closed in accordance with the practice under the practice under the practice.	nis action is non-final. vance except for formal matters	•	merits is	
Dispositi	on of Claims				
5) 6) 7) 8)	Claim(s) 8,17,18 and 21-28 is/are pending in 4a) Of the above claim(s) 17 and 18 is/are w Claim(s) is/are allowed. Claim(s) 8 and 21-28 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and an Papers	ithdrawn from consideration.			
	on Papers				
10)	The specification is objected to by the Exami The drawing(s) filed on is/are: a) a Applicant may not request that any objection to the Replacement drawing sheet(s) including the corre The oath or declaration is objected to by the	ccepted or b) objected to by ne drawing(s) be held in abeyance. ection is required if the drawing(s) in	See 37 CFR 1.85(a). s objected to. See 37 CF	, ,	
Priority u	ınder 35 U.S.C. § 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
	t(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)		mary (PTO-413) ail Date		
3) 🔲 Inforr	r No(s)/Mail Date		mal Patent Application		

Art Unit: 1638

DETAILED ACTION

1. Claims 8, 17-18 and 21-28 are pending. Claims 17-18 are withdrawn from consideration as being drawn to a nonelected invention.

- 2. The rejections of claim 9 under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement and under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter that Applicant regards as the invention is withdrawn in light of Applicant's cancellation of the claim.
- 3. The rejection of claims 8-9 are rejected under 35 U.S.C. 102(e) as being anticipated by Carozzi et al (US Patent 7,355,099, filed February 2003) is withdrawn in light of Applicant's cancellation or amendment of the claims.

Claim Objections

4. Claims 21-28 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. How or where a protein is produced or what method it is used in does not limit a claim to a protein. If applicant wishes to claim a method of using the protein, then a claim should be drawn to, for example, "A method for controlling a lepidopteran insect pest, wherein said method comprises contacting said pest with a pesticidal amount of the protein of claim 8." Claims to a nucleic acid encoding the protein or cell comprising it belong in nonelected Group I.

Art Unit: 1638

Claim Rejections - 35 USC § 103

- 5. The following is a quotation of 35 U.S.C. 103(a), which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 6. Claims 8 and 21-28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Carozzi et al (US Patent 7,355,099, filed February 2003). The rejection is repeated for the reasons of record as set forth in the Office action mailed 24 July 2009, as applied to claims 8-9 and 12-13. Applicant's arguments filed 18 December 2009 have been fully considered but they are not persuasive.

The claims are drawn to a protein of SEQ ID NO:4.

Carozzi et al teach a protein with 99% identity to the instant SEQ ID NO:4 (their SEQ ID NO:5).

```
US-10-782-020A-5
; Sequence 5, Application US/10782020A; Patent No. 7355099
; GENERAL INFORMATION:
; APPLICANT: Carozzi, Nadine
; APPLICANT: Hargiss, Tracy
; APPLICANT: Koziel, Michael G.
; APPLICANT: Duck, Nicholas B.
; APPLICANT: Carr, Brian
; TITLE OF INVENTION: AXMI-004, A Delta-Endotoxin Gene and
; TITLE OF INVENTION: Methods for Its Use
; FILE REFERENCE: 045600/274139
; CURRENT APPLICATION NUMBER: US/10/782,020A
; CURRENT FILING DATE: 2004-02-19
; PRIOR APPLICATION NUMBER: 60/448,810
  PRIOR FILING DATE: 2003-02-20
  NUMBER OF SEQ ID NOS: 11
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5
   LENGTH: 601
   TYPE: PRT
   ORGANISM: Bacillus thuringiensis
US-10-782-020A-5
```

Art Unit: 1638

```
Query Match
                   99.0%;
                        Score 3160; DB 3; Length 601;
 Best Local Similarity
                   99.0%;
                        Pred. No. 5.8e-283;
 Matches 595; Conservative
                        2;
                          Mismatches
                                        Indels
                                                        0;
                                                  Gaps
        1 MNSKEHDYLKVCNDLSDANINMERFDKNDALEIGMSIVSELIGMIPGGTALQFVFNQLWS 60
          1 MNSKEHDYLKVCNDLSDANINMERFDKNDALEIGMSIVSELIGMIPGGTALOFVFNOLWS 60
Db
        61 RLGDSGWNAFMEHVEELIDTKIEGYAKNKALSELAGIQRNLETYIQLRNEWENDIENSKA 120
QУ
          61 RLGDSGWNAFMEHVEELIDTKIEGYAKNKALSELAGIQRNLETYIQLRNEWENDIENSKA 120
Db
       121 QGKVANYYESLEQAVERSMPQFAVGNFEVPLLTVYVQAANLHLLLLRDVSVYGKRWGWSE 180
QУ
          Db
       121 QGKVANYYESLEQAVERSMPQFAVENFEVPLLTVYVQAANLHLLLLRDVSVYGKCWGWSE 180
       181 QKIKIYYDRQIKYTHEYTNHCVNWYNKGLERLKNKGSSYQDWYNYNRFRREMTLTVLDIV 240
Qy
          181 QKIKIYYDKQIKYTHEYTNHCVNWYNKGLERLKNKGSSYQDWYNYNRFRREMTLTVLDIV 240
Db
       241 ALFPHYDVQTYPITTVAQLTREVYTDPLLNFNPKLHSVSQLPSFSDMENATIRTPHLMEF 300
Qv
          241 ALFPHYDVQTYPITTVAQLTREVYTDPLLNFNPKLHSVSQLPSFSDMENATIRTPHLMEF 300
Db
       301 LRMLTIYTDWYSVGRNYYWGGHRVTSYHVGGENIRSPLYGREANQEVPRDFYFYGPVFKT 360
Qу
          301 LRMLTIYTDWYSVGRNYYWGGHRVTSYHVGGENIRSPLYGREANQEVPRDFYFYGPVFKT 360
Db
       361 LSKPTLRPLOOPAPAPPFNLRSLEGVEFHTSTGSFMYRERGSVDSFNELPPFNPVGLPHK 420
Ov
          361 LSKPTLRPLQQPAPAPPFNLRSLEGVEFHTPTGSFMYRERGSVDSFNELPPFNPVGLPHK 420
Db
       421 VYSHRLCHATFVRKSGTPYLTTGAIFSWTHRSAEETNTIESNIITQIPLVKAYQIGSGTT 480
Qv
          421 VYSHRLCHATFVRKSGTPYLTTGAIFSWTHRSAEETNTIESNIITQIPLVKAYQIGSGTT 480
Dh
       481 VRKGPGFTGGDILRRTGPGTFGDMRININAPLSERYRVRIRYASTTDLOFVTSINGATIN 540
0.7
          481 VRKGPGFTGGDILRRTGPGTFGDMRININAPLSQRYRVRIRYASTTDLQFVTSINGTTIN 540
       541 IGNFPKTINNLNTLGSEGYRTVSFSTPFSFSNAQSIFRLGIQAFSGVQEVYVDKIEFIPV 600
QУ
          541 IGNFPKTINNLNTLGSEGYRTVSFSTPFSFSNAQSIFRLGIQAFSGVQEVYVDKIEFIPV 600
Db
       601 E 601
Qν
Db
       601 E 601
```

Carozzi et al do not teach a protein of SEQ ID NO:4.

At the time the invention was made, it would have been obvious to one of ordinary skill in the art to modify the protein taught by Carozzi et al to make the instant SEQ ID NO:4. One of ordinary skill in the art would have been motivated to do so because of the suggestion of Carozzi

et al to make variants of their protein (column 11, line 40, to column 12, line 21). One of ordinary skill in the art would have been motivated to make the 6 amino acid substitutions requited to convert Carozzi et al's protein to SEQ ID NO:4 because these amino acids substitutions are a conservative substitution (amino acid 514), substitutions suggested by Carozzi et al's Fig. 1 (amino acids 175, 189, 391 and 537), or are a substitution at a site that appears to tolerate any type of amino acid (amino acid 145).

At the time the invention was made, it would have been obvious to one of ordinary skill in the art to use the resulting modified protein to control lepidopteran pests. One of ordinary skill in the art would have been motivated to do so because of the suggestion of Carozzi et al to do so (column 19, line 5, to column 20, line 36, particularly, column 19, lines 61-66). How or where a protein is produced or what method it is used in does not change the protein itself or further limit claims to the protein, as indicated above.

Applicant urges that the statement of the claims asserts that they are drawn to a method of using SEQ ID NO:4, but only claims 12-13 are drawn to a method.

This is not found persuasive because a method of using a protein includes the protein itself. Further this is made moot by Applicant's amendment of the claims.

Applicant urges that Carozzi et al is not a proper 102(e) type reference because they did not disclose a protein that resembled SEQ ID NO:4 prior to the priority of the instant application; their provisional 60/448810 discloses a single nucleotide sequence encoding a single protein that is not the same as SEQ ID NO:5 of the '099 patent (response pg 5).

This is not found persuasive because 60/448810 discloses a 629 amino acid long protein that comprises '099's SEQ ID NO:5; the protein in the provisional is longer by 28 amino acids at

Application/Control Number: 10/581,763

Art Unit: 1638

its amino terminus, but is otherwise identical. The alignment of Fig. 3 of 60/448810 is identical to that of '099's Fig. 1; thus the guidance of which amino acids to alter is provided in the provisional application.

Page 6

Conclusion

7. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne R. Kubelik, Ph.D., whose telephone number is (571) 272-0801. The examiner can normally be reached Monday through Friday, 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg, can be reached at (571) 272-0975.

The central fax number for official correspondence is (571) 273-8300.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Art Unit: 1638

March 3, 2010

/Anne R Kubelik/ Primary Examiner, Art Unit 1638